PharmAust Ltd. Stock
€0.24
Your prediction
PharmAust Ltd. Stock
Pros and Cons of PharmAust Ltd. in the next few years
Pros
Cons
Performance of PharmAust Ltd. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
PharmAust Ltd. | 30.390% | 22.280% | 27.568% | 349.524% | 283.740% | 310.435% | 1375.000% |
Biotec Pharmacon ASA | - | 6.624% | -0.598% | -26.008% | -30.694% | -64.255% | 494.048% |
Immutep Ltd. | -2.680% | 0.000% | 5.825% | 42.298% | 4.808% | -22.143% | 67.692% |
TALI Digital Ltd. | - | 0.000% | 0.000% | 0.000% | 0.000% | -97.917% | -90.000% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.PharmAust, a pharmaceuticals company, has shown mixed financial results according to the data provided. As a financial analyst, it is essential to examine the overall trends observed in their financial statements, including balance sheets, cash flow, and income statements.
*Pros: * 1. Positive Net Working Capital: PharmAust displayed a positive net working capital over the last three years, reaching $2,564,991 AUD for the year ending June 2022. This indicates that the company has enough short-term assets to cover its short-term liabilities.
Cash Position: PharmAust's cash position has been relatively stable, even though it experienced a decrease in the period ending June 2022. The company maintains a cash balance that allows for flexibility in funding its operations, expansion, and other potential business ventures.